192 related articles for article (PubMed ID: 37450376)
21. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
[TBL] [Abstract][Full Text] [Related]
22. The Future of CAR T-Cell Therapy.
Slater H
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914200
[No Abstract] [Full Text] [Related]
23. CAR T cells mimicking an aggressive lymphoma.
Song JY; Herrera AF
Blood; 2019 Mar; 133(13):1517. PubMed ID: 30923108
[No Abstract] [Full Text] [Related]
24. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
25. Four cases of central nervous system involvement of breast malignant lymphoma.
Yamazaki H; Hanada M; Kitada M; Kuyama J; Sato T; Nishikubo M; Ishida T; Inoue T; Inoue T
Jpn J Clin Oncol; 2003 Aug; 33(8):399-403. PubMed ID: 14523060
[TBL] [Abstract][Full Text] [Related]
26. CAR T-cell therapy in refractory large B-cell lymphoma.
Stirrups R
Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
[No Abstract] [Full Text] [Related]
27. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
[TBL] [Abstract][Full Text] [Related]
28. Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model.
Tully S; Feng Z; Grindrod K; McFarlane T; Chan KKW; Wong WWL
JCO Clin Cancer Inform; 2019 Oct; 3():1-9. PubMed ID: 31644324
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.
Akingbemi W; Kurtz G; Yegya-Raman N; Plastaras JP; Schuster SJ; Chong EA
Leuk Lymphoma; 2024 Jun; 65(6):860-863. PubMed ID: 38451075
[No Abstract] [Full Text] [Related]
31. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
[TBL] [Abstract][Full Text] [Related]
32. Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma.
Jalbert JJ; Wu N; Chen CI; Ambati S; Ge W; Arnason JE
Adv Ther; 2022 Jun; 39(6):2630-2640. PubMed ID: 35397110
[TBL] [Abstract][Full Text] [Related]
33. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma.
Gajra A; Jeune-Smith Y; Kish J; Yeh TC; Hime S; Feinberg B
Immunotherapy; 2020 Jul; 12(10):725-732. PubMed ID: 32552151
[No Abstract] [Full Text] [Related]
34. Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma.
Bajwa A; Huang Y; Li R; Denlinger N; Brammer J; Penza S; Saad A; Jaglowski S; Kittai AS
Leuk Lymphoma; 2022 Jun; 63(6):1492-1495. PubMed ID: 35109749
[No Abstract] [Full Text] [Related]
35. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma.
Lutfi F; Holtzman N; Siglin J; Bukhari A; Mustafa Ali M; Kim D; Sanchez-Petitto G; Gottlieb D; Ruehle K; Hutnick E; Gahres N; Hankey K; Lee S; Kocoglu M; Yared J; Hardy N; Rapoport A; Dahiya S
Br J Haematol; 2021 Jan; 192(1):212-216. PubMed ID: 33169845
[No Abstract] [Full Text] [Related]
38. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
39. PRESUMPTIVE RECURRENCE OF INTRAOCULAR LYMPHOMA DESPITE CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY.
Taher A; Abadir E; McCluskey P; Hamad N; Lo TH; Heydon P
Retin Cases Brief Rep; 2023 Sep; 17(5):562-566. PubMed ID: 37643043
[TBL] [Abstract][Full Text] [Related]
40. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.
Cliff ERS; Merryman RW; Armand P; Jacobson CA
Nat Med; 2022 Dec; 28(12):2458-2459. PubMed ID: 36348063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]